Foell, Dirk
Saers, Melanie
Park, Carolin
Brix, Ninna
Glerup, Mia
Kessel, Christoph
Wittkowski, Helmut
Hinze, Claas
Berntson, Lillemor
Fasth, Anders
Myrup, Charlotte
Nordal, Ellen
Rygg, Marite
Hasle, Henrik
Albertsen, Birgitte Klug
Herlin, Troels
Holzinger, Dirk
Niederberger, Christian
Schlüter, Bernhard
Funding for this research was provided by:
Universitätsklinikum Münster
Article History
Received: 17 August 2023
Accepted: 9 October 2023
First Online: 25 October 2023
Declarations
:
: The patients with fever of unknown origin were collected at Muenster University as reported before. The study was approved by the Medical Ethics Committee at the University of Muenster, Muenster, Germany (Az 2014–637-f-S). The ALL cohort included consecutive cases from Aalborg and Aarhus University Hospitals. The study was approved by the Medical Ethics Committee (1–10-72–206-19) and the Danish Data Protection Agency (1–16-02–214-16). Patients with nonsystemic JIA were from the Nordic JIA cohort as previously described in detail. The study was approved by the national research committees (1–10-72–280-13, 2012/2051, Dnr 2014/413–31, 174/13/03/ 03/2014). All patients/caregivers provided informed consent, and the study is performed in accordance with the Helsinki Declaration.
: Not applicable.
: DF received speaker fees/honoraria from Chugai-Roche, Novartis and SOBI as well as research support from Novartis, Pfizer and SOBI; CK has received consulting fees from Novartis and Swedish Orphan Biovitrum (SOBI) and received research support from Novartis. HW has received honoraria (lecture fees) from Novartis and Takeda, and travel support from Octapharma and CSL-Behring; CH has received travel support from Pfizer; CM received speaker fees/honoraria from Novartis, Sobi and MSD; DH received speaker fees/honoraria from Novartis and SOBI; CN is employee of BÜHLMANN Laboratories AG. The other authors have no competing interests to disclose.